Clinical trial · Interventional
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
NCT00644488CI-TRIAL-00004340completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-641988 (AR#2) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A1
- description
- Active
- interventionNames
- Drug: BMS-641988 (AR#2)
Primary outcomes (1)
- measure
- To assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer
- timeFrame
- throughout the study
Secondary outcomes (4)
- measure
- To evaluate the pharmacokinetics of BMS-641988 and the metabolites BMS-501949 and BMS-570511
- timeFrame
- at cycle 1 day 1, day 15 and day 29
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with castration-resistant prostate cancer and serum testosterone ≤50 ng/dL progressive to current therapy who satisfy the inclusion and exclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.